ALSO NOTED: Genzyme can't make Myozyme at Boston plant; Ranbaxy, Orchid forge drug-and-API deal;

> FDA won't let Genzyme make its uber-expensive Pompe disease treatment Myozyme at its Boston plant because of a small difference between the batches of Myozyme Genzyme makes now and the new larger batches it was to produce; the regulatory crackdown will leave the drug in short supply in the U.S. and depress Genzyme's 2008 earnings. Report

> Ranbaxy inked a deal with Orchid Chemicals & Pharmaceuticals for multiple finished dosages and active pharmaceutical ingredients. Release

> A Nevada judge ordered Wyeth to post a $58 million bond and pay $1.6 million in attorney's fees for acting in 'bad faith' during settlement talks in the case of three women who sued over the Prempro hormone replacement therapy. Report

> Two drug companies outsourced chunks of their IT systems: Nycomed hired British Telecommunications and Hewlett-Packard to provide it with IT infrastructure, and Janssen Pharmaceuticals tapped Porthus to manage all its electronic customs programming in Belgium. Report

> Celgene got regulatory approval to sell its thalidomide drug in the EU, for use in combination with two other meds for treating multiple myeloma. Report

> Roche's Japanese unit Chugai upped its full-year profit expectations to ¥29 billion from ¥17 billion after government drug-price cuts came in smaller than expected. Report

> Mylan got the FDA nod for its copycat version of AstraZeneca's blood pressure pill Plendil. Report

> Four of San Diego's biggest research institutions are teaming up to form the San Diego Consortium for Regenerative Medicine, a group aimed at advancing stem cell work. And they're planning a $115 million research "collaboratory" that would open in 2010. Report

> Cambridge, MA-based Stromedix has landed $25 million in a Series B round of venture capital. Report

> The bill on sequencing a genome has fallen from a few billion dollars to about $60,000 in just five years. And now two companies want to use nanotech to knock that price down to just $100. Report

> University of Cincinnati researcher Melissa DelBello is getting some added scrutiny for failing to disclose large sums of money she received from AstraZeneca a year after completing a study of Seroquel for bipolar disease. Report

And Finally... "Chemo brain" symptoms may not be byproducts of fatigue and depression associated with cancer treatment, but side effects of a common chemo drug, 5-fluorouracil, a new study found. Report

Suggested Articles

Pfizer isn't giving up in biosims. This week, it unveiled launches to three Roche blockbusters, with two already on the market.

Novo Nordisk is betting big on GLP-1 Saxenda in its global obesity push, but England's cost watchdog is unimpressed with the drug's long-term outlook.

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.